bunyavirida
famili
gener
sensit
ribavirin
prospect
random
doubleblind
placebocontrol
trial
patient
serolog
confirm
hantaan
viru
peopl
republ
china
found
sevenfold
decreas
mortal
among
ribavirintr
patient
studi
confirm
benefit
ribavirin
found
effect
cchf
viru
cchfv
vitro
year
sinc
discoveri
mechan
action
ribavirin
still
remain
controversi
ribavirin
clinic
administ
nucleosid
adenosin
kinas
cellular
enzym
respons
convers
ribavirin
monophosp
rmp
box
antivir
mechan
ribavirin
fulli
defin
relat
alter
cellular
nucleotid
pool
inhibit
viral
messeng
rna
synthesi
intracellular
phosphoryl
mono
di
triphosph
deriv
mediat
host
cell
enzym
uninfect
respiratori
syncyti
viru
rsv
infect
cell
predomin
deriv
triphosph
intracellular
elimin
half
life
less
h
ribavirin
triphosph
gener
predomin
metabolit
ergonul
et
al
broad
spectrum
antivir
activ
ribavirin
potenti
attribut
multipl
mechan
action
purin
analog
function
multipl
cellular
viral
process
import
aspect
antivir
activ
ribavirin
may
stem
abil
act
via
multipl
mechan
simultan
five
distinct
mechan
suggest
action
potenti
other
ribavirin
monophosph
competit
inhibit
cellular
dehydrogenas
interfer
synthesi
guanosin
triphosph
gtp
thu
nucleic
acid
synthesi
gener
ribavirin
triphosph
also
competit
inhibit
gtp
depend
viral
messeng
rna
ribavirin
inhibitor
inosin
monophosph
dehydrogenas
inhibitor
rna
cap
polymeras
inhibitor
lethal
mutagen
immunomodulatori
agent
ribavirin
also
postul
act
via
anoth
indirect
antivir
mechan
enhanc
host
tcell
respons
conclus
stem
observ
hepat
c
viru
hcv
infect
patient
ribavirin
reduc
serum
alanin
aminotransferas
alt
level
without
significantli
reduc
level
circul
hcv
rna
determin
via
pcr
ribavirin
thought
induc
switch
thelper
cell
phenotyp
type
type
thelper
type
respons
associ
cellular
immun
express
tumor
necrosi
vitro
inhibitori
concentr
ribavirin
may
revers
inhibit
macromolecular
synthesi
prolifer
uninfect
cell
suppress
lymphocyt
respons
alter
cytokin
profil
vitro
howev
effect
studi
vivo
cytokin
found
higher
among
fatal
cchf
patient
wherea
signific
differ
level
favor
fatal
case
howev
immunomodulatori
effect
ribavirin
studi
cchfv
yet
vitro
studi
ribavirin
shown
inhibit
viral
activ
cchf
viral
strain
appear
sensit
other
contrast
dose
ribavirin
least
nine
time
greater
requir
induc
compar
inhibitori
effect
yield
rift
valley
fever
viru
drug
shown
inhibit
replic
monkey
rodent
intraperiton
infect
infant
mice
cchf
viru
viru
titer
liver
remain
significantli
higher
organ
except
serum
within
liver
viru
antigen
first
found
immunofluoresc
assay
ifa
kupffer
cell
follow
extens
hepat
spread
later
viru
found
organ
includ
brain
heart
ribavirin
treatment
significantli
reduc
infant
mous
mortal
extend
geometr
mean
time
death
ribavirin
treatment
reduc
cchf
viru
growth
liver
significantli
decreas
prevent
viremia
clinic
data
relat
effect
ribavirin
stem
studi
chronic
infect
hcv
infect
effect
ribavirin
use
cchfv
infect
evidenc
random
clinic
trial
effect
use
describ
observ
studi
first
clinic
report
observ
limit
three
healthcar
worker
hcw
infect
cchfv
infect
three
patient
sever
ill
low
platelet
white
blood
cell
count
rais
aspart
transaminas
evid
impair
haemostasi
accord
sever
criteria
defin
swanepoel
estim
probabl
death
patient
becam
afebril
haematolog
biochem
abnorm
return
normal
within
h
ribavirin
treatment
made
complet
recoveri
find
found
encourag
use
ribavirin
cchfv
infect
constitut
evid
efficaci
studi
ribavirin
introduc
use
cchfv
infect
mardani
et
al
compar
fatal
rate
among
patient
suspect
cchf
receiv
treatment
oral
ribavirin
mani
treat
patient
suspect
cchf
surviv
treat
patient
confirm
cchf
surviv
efficaci
oral
ribavirin
among
patient
confirm
cchf
among
patient
suspect
cchf
studi
use
histor
control
stratifi
patient
accord
sever
patient
ergonul
et
al
describ
role
ribavirin
therapi
confirm
cchf
patient
patient
consid
sever
case
cchf
eight
patient
given
ribavirin
eight
surviv
studi
result
suggest
use
ribavirin
especi
sever
case
fig
ergonul
et
al
case
studi
group
accord
sever
criteria
defin
swanepoel
ozkurt
et
al
describ
efficaci
ribavirin
therapi
cchf
among
confirm
cchf
patient
eastern
turkey
mean
recoveri
time
shorter
case
treat
ribavirin
control
need
blood
blood
product
mean
hospit
durat
fatal
rate
hospit
expenditur
valu
significantli
differ
two
group
patient
receiv
ribavirin
almost
author
claim
could
perform
random
clinic
trial
rct
ethic
constraint
lack
random
main
critic
observ
studi
howev
sometim
observ
studi
could
give
qualifi
inform
could
well
design
research
awar
potenti
confound
perform
clinic
outcom
studi
ribavirin
use
cchf
signific
confound
sever
infect
might
differ
mild
sever
form
diseas
sever
reason
see
also
chapter
number
day
onset
might
differ
patient
could
get
ribavirin
earlier
prehemorrhag
phase
infect
wherea
patient
could
get
ribavirin
later
phase
hemorrhag
phase
infect
sever
gastrointestin
symptom
might
differ
patient
get
drug
via
oral
rout
sever
hematemesi
paramet
import
pharmacolog
effect
ribavirin
save
sever
case
observ
compar
studi
ribavirin
given
given
group
would
misclassif
bia
favor
use
ribavirin
patient
would
receiv
ribavirin
would
usual
mild
case
well
design
observ
studi
minim
effect
confound
avoid
misclassif
bia
accord
clinic
observ
case
effect
treatment
cchf
could
consid
hypothet
two
phase
fig
first
phase
start
exposur
viru
character
viremia
usual
last
day
clinic
term
period
start
onset
prehemorrhag
symptom
fever
myalgia
nausea
vomit
end
bleed
variou
site
antivir
effect
ribavirin
like
occur
first
phase
second
phase
character
declin
viremia
bleed
variou
site
start
phase
cytokin
releas
extens
coagul
cascad
disrupt
patient
dissemin
intravascular
coagul
note
antivir
action
ribavirin
less
like
phase
immunomodulatori
effect
known
yet
altern
drug
target
dissemin
intravascular
coagul
dic
sepsi
could
consid
second
phase
diseas
cours
ribavirin
activ
taken
gastrointestin
nucleosid
transport
locat
proxim
small
bowel
oral
bioavail
averag
approxim
extens
accumul
occur
plasma
steadi
state
reach
week
food
increas
plasma
level
substanti
ingest
food
may
prudent
follow
singl
multipl
oral
dose
mg
mg
peak
plasma
concentr
averag
respect
intraven
dose
mg
mg
plasma
concentr
averag
approxim
respect
appar
volum
distribut
larg
lkg
due
ribavirin
uptak
cell
plasma
protein
bind
neglig
elimin
ribavirin
complex
plasma
half
life
averag
h
singl
dose
increas
approxim
h
steadi
state
ribavirin
triphosph
ergonul
et
al
effect
treatment
cchf
consid
two
phase
first
phase
start
exposur
viru
character
viremia
usual
last
day
clinic
term
period
start
onset
prehemorrhag
symptom
fever
myalgia
nausea
vomit
end
bleed
variou
site
ribavirin
like
effect
first
phase
second
phase
character
declin
viremia
clinic
onset
bleed
variou
site
immunolog
mechan
cytokin
storm
disrupt
coagul
cascad
patient
dissemin
intravascular
coagul
occur
patient
treatment
altern
consid
like
ribavirin
less
effect
phase
ribavirin
could
effect
second
phase
mainli
immunomodulatori
effect
howev
immunomodul
suggest
main
action
ribavirin
concentr
erythrocyt
red
blood
cell
level
gradual
decreas
day
hepat
metabol
renal
excret
ribavirin
metabolit
princip
rout
elimin
hepat
metabol
involv
deribosyl
hydrolysi
yield
triazol
carboxamid
ribavirin
clearanc
decreas
threefold
advanc
renal
insuffici
cl
cr
mlmin
drug
use
cautious
patient
creatinin
clearanc
less
mlmin
oral
intraven
form
avail
mani
countri
dosag
given
box
total
durat
treatment
defin
day
laboratori
result
get
better
ribavirin
could
stop
effectiv
iv
oral
form
compar
yet
emerg
viral
resist
ribavirin
document
virus
report
sindbi
hcv
although
possibl
select
cell
phosphoryl
activ
form
system
ribavirin
caus
doserel
revers
anemia
due
extravascular
hemolysi
suppress
bone
marrow
associ
increas
occur
reticulocyt
count
serum
bilirubin
iron
uric
acid
concentr
high
ribavirin
triphosph
level
may
caus
oxid
damag
membran
lead
erythrophagocytosi
reticuloendotheli
system
half
life
ribavirin
metabolit
rel
short
cultur
fibroblast
lymphoblast
although
nucleotid
much
stabl
erythrocyt
accumul
ribavirin
erythrocyt
respons
revers
hemolyt
anemia
side
effect
clinic
ribavirin
therapi
bolu
intraven
infus
may
caus
rigor
chronic
hepat
c
patient
receiv
combin
interferonribavirin
therapi
discontinu
treatment
box
action
mechan
antivir
agent
rna
virus
replic
strategi
rna
virus
reli
either
enzym
virion
whole
infect
viral
particl
synthes
mrna
viral
rna
serv
mrna
mrna
translat
variou
viral
protein
includ
rna
polymeras
direct
synthesi
viral
mrna
earli
side
effect
addit
interferon
toxic
oral
ribavirin
increas
risk
fatigu
cough
rash
pruritu
nausea
insomnia
dyspnea
depress
particularli
anemia
patient
requir
ribavirin
dose
reduct
anemia
hemolyt
anemia
hypocalcemia
hypomagnesemia
report
patient
receiv
ribavirin
sever
acut
respiratori
syndrom
sar
howev
advers
event
relat
ribavirin
therapi
note
among
cchf
patient
mainli
two
reason
acut
cours
diseas
might
allow
time
observ
side
effect
overshadow
diseas
find
potenti
advers
event
anemia
preclin
studi
indic
ribavirin
teratogen
embryotox
oncogen
possibl
gonadotox
vivo
genotox
ribavirin
among
three
patient
cchf
studi
micronucleu
sister
chromatid
exchang
test
found
higher
among
three
patient
right
ribavirin
therapi
month
later
test
result
becam
normal
find
reveal
ribavirin
revers
vivo
genotox
effect
human
prevent
possibl
teratogen
side
effect
month
requir
washout
follow
cessat
longterm
treatment
use
ribavirin
contraind
among
pregnant
women
ribavirin
food
drug
administr
fda
pregnanc
categori
x
potenti
bleed
foci
patient
consid
conserv
measur
taken
use
histamin
receptor
blocker
peptic
ulcer
patient
avoid
intramuscular
inject
use
aspirin
drug
action
coagul
system
nonsteroid
antiinflammatori
drug
avoid
fluid
electrolyt
balanc
also
monitor
meticul
support
therapi
essenti
part
case
manag
includ
administr
thrombocyt
fresh
frozen
plasma
ffp
sometim
erythrocyt
prepar
replac
therapi
blood
product
perform
check
complet
blood
count
done
one
two
time
day
clinic
practic
check
thrombocyt
level
day
would
suffici
thrombocyt
solut
ffp
product
replac
accord
deficit
individu
patient
figur
depict
tremend
amount
thrombocyt
solut
ffp
given
patient
turkey
fatal
case
receiv
significantli
p
higher
amount
thrombocyt
suspens
ffp
fig
sometim
hard
decid
start
stop
blood
product
replac
therefor
review
gener
rule
platelet
ffp
use
adapt
cchfv
infect
randomdonor
platelet
rdp
platelet
concentr
prepar
separ
platelet
singl
unit
whole
blood
minimum
platelet
suspend
approxim
ml
plasma
u
platelet
separ
whole
blood
within
h
collect
depend
contain
rdp
store
shelf
life
vari
day
store
room
temperatur
pheresisapheresi
platelet
singledonor
platelet
sdp
platelet
collect
apheresi
techniqu
singl
donor
use
blood
cell
separ
contain
minimum
platelet
suspend
ml
plasma
apheresi
platelet
shelf
life
rang
h
day
store
room
temperatur
product
account
platelet
transfus
develop
countri
hlamatch
platelet
concentr
donor
apheresi
platelet
concentr
select
donor
human
leukocyt
antigen
hla
type
match
recipi
hla
type
due
develop
alloimmun
hla
apheresi
platelet
product
consid
hlamatch
platelet
compon
use
platelet
transfus
indic
control
activ
bleed
prevent
hemorrhag
associ
defici
platelet
number
function
platelet
use
prophylact
prevent
bleed
platelet
count
less
grow
trend
reduc
prophylact
platelet
transfus
trigger
count
low
stabl
patient
without
signific
hemorrhag
dose
infus
rate
rdp
averag
adult
platelet
concentr
dose
one
unit
rdp
per
kg
bodi
weight
grow
trend
unit
state
defin
standard
dose
platelet
concentr
standard
vari
among
differ
institut
u
u
u
platelet
concentr
infus
per
transfus
episod
platelet
unit
usual
pool
one
bag
transfus
servic
prior
issu
infus
within
h
rate
depend
patient
abil
toler
volum
rdp
may
volum
reduc
pool
rdp
undergo
centrifug
allow
separ
platelet
platelet
poor
plasma
excess
platelet
poor
plasma
remov
therapeut
dose
concentr
approxim
ml
volumereduc
platelet
infus
rapidli
nonvolumereduc
platelet
must
infus
within
h
pool
pheresi
plateletsdp
one
sdp
concentr
consid
therapeut
dose
equival
six
unit
rdp
sdp
infus
rapidli
possibl
depend
patient
abil
toler
infus
volum
hlamatch
platelet
dose
infus
rate
similar
sdp
expect
outcom
platelet
transfus
result
prevent
resolut
bleed
caus
thrombocytopenia
platelet
dysfunct
gener
rule
platelet
count
obtain
h
postinfus
averages
adult
receiv
u
rdp
per
kg
bodi
weight
one
sdp
dose
posttransfus
platelet
increment
patient
smaller
increment
h
postinfus
platelet
count
perform
min
next
platelet
transfus
min
posttransfus
increment
minim
increas
possibl
refractori
caus
alloimmun
entertain
antibodyrel
platelet
destruct
often
relat
develop
hlaspecif
antibodi
respons
foreign
donor
hla
antigen
patient
consid
hlamatch
platelet
transfus
crossmatch
platelet
concentr
poor
posttransfus
platelet
surviv
addit
caus
alloimmun
often
seen
conjunct
fever
sepsi
dissemin
intravascular
coagul
other
patient
set
consid
refractori
nonimmunolog
basi
expect
benefit
hlamatch
platelet
transfus
patient
lifethreaten
hemorrhag
may
requir
larger
platelet
dose
therapeut
current
controversi
grow
whether
patient
requir
prophylact
platelet
transfus
would
benefit
repetit
smalldos
platelet
transfus
better
use
extra
highdos
platelet
transfus
random
wellcontrol
studi
answer
issu
yet
done
cchf
sinc
dissemin
intravascular
coagul
occur
diseas
cours
platelet
destruct
expect
rapid
increment
plt
level
transfus
may
observ
ffp
plasma
separ
whole
blood
frozen
within
h
collect
normal
level
clot
factor
anticoagul
three
differ
type
ffp
avail
transfus
standard
ffp
describ
ii
donorretest
ffp
plasma
donat
frozen
store
day
donor
return
infecti
diseas
test
still
neg
origin
unit
releas
inventori
donorretest
plasma
valu
close
window
period
infecti
diseas
current
test
hiv
hvc
iii
pool
solvent
detergenttr
plasma
frozen
plasma
sent
commerci
compani
treat
solvent
deterg
process
prevent
transmiss
envelop
virus
ie
hiv
hcv
valu
product
prevent
transmiss
envelop
viru
blood
transfus
pool
product
recipi
expos
donor
transfus
unit
frozen
plasma
ffp
indic
replenish
clot
factor
patient
demonstr
defici
prothrombin
time
partial
thromboplastin
time
greater
time
normal
intern
normal
ratio
inr
ffp
commonli
use
set
acquir
coagulopathi
patient
liver
diseas
dic
excess
warfarin
effect
averag
adult
dose
determin
clinic
situat
underli
diseas
process
reason
administ
plasma
dose
mlkg
bodi
weight
u
ffp
follow
laboratori
evalu
determin
respons
decid
interv
dose
infus
rate
determin
basi
patient
clinic
need
hemodynam
statu
plasma
contain
red
cell
therefor
crossmatch
requir
abo
type
donor
compat
recipi
ffp
thaw
must
transfus
h
thaw
use
coagul
factor
replac
plasma
thaw
maintain
refriger
state
day
loss
coagul
factor
v
greater
decreas
factor
viii
expect
outcom
improv
coagul
factor
defici
expect
assess
prothrombin
time
inr
partial
thromboplastin
time
specif
factor
assay
altern
could
consid
possibl
pathogenet
mechan
infect
therapeut
agent
consid
hemophagocystosi
dic
could
also
studi
cchf
infect
agent
consid
dic
shown
tabl
corticosteroid
accompani
ribavirin
report
use
earli
stage
cchf
howev
experi
limit
six
patient
algorithm
manag
case
suggest
tabl
ergonul
et
al
dissemin
intravascular
coagul
dic
result
activ
coagul
vascular
tree
acceler
platelet
consumpt
almost
alway
seen
dic
distinguish
immun
thrombocytopenia
find
prolong
prothrombin
partial
th
romboplastin
time
decreas
plasma
fibrinogen
elev
plasma
fibrinfibrinogen
split
product
dic
seen
infect
eg
viral
rickettsi
bacteri
malari
infect
obstetr
catastroph
abruptio
placenta
retain
dead
fetu
syndrom
malign
trauma
vascular
abnorm
giant
hemangioma
aortic
aneurysm
gener
treatment
direct
toward
correct
underli
caus
support
plasma
platelet
transfus
may
requir
bleed
complic
caus
correct
thrombocytopenia
gradual
resolv
infect
control
followup
relaps
occur
diseas
therefor
need
follow
case
hcw
expos
viru
follow
complet
blood
count
biochem
test
day
histor
treatment
crimeancongo
hemorrhag
fever
cchf
limit
poorli
studi
howev
hemorrhag
fever
viru
infect
approach
follow
differ
therapeut
strategi
administr
hightit
neutral
antibodi
andor
ii
treatment
antivir
drug
recent
time
immunotherapi
approach
describ
use
passiv
transfer
cchf
convalesc
sera
recov
patient
specif
use
immunotherapi
therapeut
approach
discuss
section
depend
site
interact
molecular
target
antivir
drug
may
classifi
follow
orotidin
monophosph
decarboxylas
inhibitor
ie
pryrazofurin
inosin
monophosph
dehydogeneas
inhibitor
ie
ribavirin
deriv
cytidin
triphosph
synthas
inhibitor
ie
cyclopentenylcytosin
sadenosylhomocystein
hydrolas
inhibitor
ie
neplanocin
polyanion
substanc
ie
sulfat
polym
interferon
immunomodulateror
current
specif
antivir
drug
cchf
howev
report
exist
describ
potenti
antivir
effect
ribavirin
mention
random
control
studi
exist
confirm
potenc
ribavirin
cchf
anoth
interest
area
treatment
antivir
activ
interferon
immunomodul
viral
infect
almost
hemorrhag
fever
virus
shown
sensit
interferon
howev
order
develop
agent
whose
function
exploit
antivir
activ
interferon
knowledg
antivir
mechan
interferon
cchfv
requir
role
interferon
interferoninduc
antivir
protein
discuss
section
past
year
sever
group
becom
interest
studi
cchfv
potenti
abus
bioterror
weapon
research
increas
knowledg
basic
biolog
cchfv
may
lead
improv
therapi
exampl
could
find
inhibitor
viral
protein
process
last
decad
potenti
rna
interfer
therapeut
agent
viru
infect
discuss
recent
mani
studi
display
efficaci
chemic
synthes
short
interfer
rna
tool
combat
divers
group
virus
howev
mention
rna
interfer
use
therapeut
agent
sever
question
need
address
transient
effect
short
interfer
rna
deliveri
method
cell
uptak
host
respons
infect
compris
two
gener
categori
innat
immun
rapid
phylogenet
nonspecif
respons
infect
adapt
immun
long
live
highlyspecif
immun
respons
infect
innat
immun
describ
essenti
immun
respons
emerg
virus
central
innat
immun
respons
larg
heterogen
group
peptid
mediat
interferon
chemokin
interleukin
growth
factor
molecul
part
complex
network
regul
immun
inflammatori
respons
interferon
produc
leukocyt
fibroblast
respons
viral
infect
result
induct
antivir
pathway
within
period
hour
postinfect
interferon
long
histori
clinic
applic
viral
diseas
earli
demonstr
potent
antivir
effect
patient
chronic
hepat
c
recent
time
sever
group
studi
antivir
activ
interferon
hemorrhag
fever
virus
studi
clearli
demonstr
interferon
signific
antivir
activ
hemorrhag
fever
virus
vitro
anim
model
howev
date
clinic
data
address
effect
interferon
viral
hemorrhag
fever
particular
cchfv
moreov
use
interferon
therapeut
agent
hemorrhag
fever
diseas
pose
signific
clinic
challeng
better
understand
interferon
action
essenti
current
therapi
optim
also
new
strategi
therapi
approach
isaac
lindenmann
discov
antivir
activ
interferon
class
molecul
almost
year
ago
today
interferon
divid
two
group
interferon
type
ii
type
interferon
major
player
antivir
defens
almost
known
virus
type
interferon
includ
least
subtyp
gene
one
gene
type
interferon
antivir
activ
well
antiprolif
immunomodulatori
activ
virusinfect
stimul
cell
upregul
secret
interferon
type
secret
interferon
induc
cell
express
potent
antivir
protein
activ
addit
antivir
mechan
limit
viral
spread
antivir
activ
directli
coupl
interferon
molecul
per
se
rather
molecul
act
indirectli
induc
interferonstimul
gene
isg
turn
establish
antivir
phase
target
cell
type
interferon
trigger
express
larg
number
isg
isg
antivir
antiprolif
immunomodulatori
function
interferoninduc
protein
includ
transcript
factor
enzym
cytokin
chemokin
glycoprotein
although
larg
number
molecul
need
character
antivir
protein
studi
detail
bestcharacter
interferoninduc
antivir
protein
mx
gtpase
oligoadenyl
synthetas
oa
rnasel
protein
kinas
r
pkr
mxa
found
one
major
antivir
protein
larg
group
virus
includ
virus
ortomyxo
paramyxo
togovirida
rhabdovirida
picrnavirida
hepdnavirida
famili
mxa
belong
dynamin
super
famili
larg
gtpase
whose
member
function
varieti
intracellular
transport
process
recent
studi
clearli
demonstr
mxa
signific
antivir
activ
cchfv
andersson
cowork
demonstr
mxa
coloc
interact
cchfv
nucleocapsid
protein
perinuclear
region
infect
cell
therefor
suggest
interact
inhibit
viru
replic
process
similar
result
observ
member
bunyavirida
result
togeth
impli
anim
bunyavirida
may
restrict
intracellular
growth
mxa
probabl
mechan
anoth
recent
report
andersson
cowork
show
isg
induc
human
endotheli
hepatoma
cell
suffici
inhibit
cchfv
growth
significantli
yet
despit
effect
cchfv
still
run
devast
cours
estim
cchfv
caus
mortal
rate
beli
tween
infect
patient
like
explan
interferon
induc
insuffici
level
late
cours
infect
put
mxa
antivir
protein
place
combat
cchfv
urgent
need
addit
protein
potenti
import
antivir
activ
rnaspecif
adenosin
deaminas
adar
promyelocyt
leukemia
protein
pml
guanylatebind
protein
interferoninduc
exonucleas
specif
degrad
ssrna
express
inhibit
viral
replic
vesicular
stomat
viru
human
immunodefici
viru
cell
cultur
recent
studi
weber
mirazimi
clearli
shown
antivir
activ
cchfv
far
unknown
mechan
unpublish
critic
need
identifi
new
effect
treatment
viral
hemorrhag
fever
particular
cchfv
one
interest
issu
interferon
immunomodul
present
knowledg
antivir
activ
interferon
system
still
limit
howev
better
understand
complic
interact
virus
innat
immun
respons
help
design
new
antivir
treatment
therapi
infect
cchfv
elicit
antibodi
viru
present
sever
day
onset
ill
patient
die
cchf
usual
develop
measur
antibodi
respons
like
even
patient
low
level
cchfvspecif
igg
still
could
reinfect
exampl
shown
west
african
sheep
play
central
role
mainten
cycl
cchf
viru
diseaseendem
area
serv
host
viru
tick
vector
even
sheep
infect
previous
anticchf
viru
igg
reinfect
transmit
viru
cchfvspecif
igm
remain
elev
day
infect
report
whether
elev
level
could
protect
infect
reinfect
howev
antibodi
could
play
protect
role
secondari
transmiss
virul
viru
like
diminish
transmiss
possibl
due
exist
subpopul
viru
adapt
host
select
passag
anoth
vertebr
host
subpopul
seem
less
virul
might
alter
capac
transmiss
consist
observ
infect
secondari
case
unusu
unless
heavi
exposur
viru
contamin
tissu
occur
howev
efficaci
treatment
secondari
transmiss
difficult
evalu
lack
control
risk
fatal
outcom
secondari
case
high
current
specif
antivir
therapi
cchf
approv
use
human
fda
formalininactiv
suckl
mous
brainbas
vaccin
use
bulgaria
part
eastern
europ
former
soviet
union
protect
cchfv
infect
rostov
region
former
soviet
union
person
receiv
vaccin
show
high
frequenc
detect
antibodi
likewis
vaccin
given
sever
hundr
human
volunt
bulgaria
result
high
antibodi
induct
rel
small
target
popul
person
risk
contract
cchfv
largescal
develop
product
cchf
vaccin
modern
standard
seem
unlik
earli
recognit
possibl
benefit
treatment
use
serum
prepar
blood
recov
cchf
patient
gammaglobulin
obtain
immun
hors
recent
time
bulgarian
investig
suggest
immunotherapi
treatment
seven
patient
sever
cchf
via
passiv
simultan
transfer
two
differ
specif
immunoglobulin
prepar
cchfbulin
intramuscular
use
cchfvenin
intraven
use
prepar
plasma
cchf
survivor
donor
boost
one
dose
cchf
vaccin
result
quick
recoveri
patient
side
effect
observ
patient
discharg
good
health
although
control
group
case
sever
averag
case
per
year
report
bulgaria
firm
evid
valu
lack
previou
experi
suggest
case
prognosi
unfavor
even
patient
treat
intramuscular
formul
cchfbulin
year
patient
die
investig
attribut
success
approach
quick
distribut
antibodi
circul
import
acut
infect
combin
sustain
even
increas
antibodi
concentr
muscl
depot
suggest
intraven
prepar
use
treatment
case
cchf
advanc
develop
monoclon
antibodi
antibodi
engin
rais
hope
new
candid
drug
prevent
treatment
cchfv
infect
immunotherapi
cchf
base
polyclonl
antibodi
obtain
serum
immun
anim
human
although
prepar
could
effect
use
monoclon
antibodi
could
allow
better
control
composit
therapeut
prepar
case
could
effect
exampl
human
monoclon
antibodi
synagi
first
monoclon
antibodi
yet
licens
infecti
diseas
prefer
two
avail
licens
product
situat
second
one
rsvigiv
respigam
solut
igg
enrich
neutral
antibodi
rsv
howev
mab
recogn
singl
epitop
may
limit
use
pathogen
exhibit
genet
variat
problem
could
solv
gener
mab
conserv
epitop
andor
use
mab
cocktail
recent
mous
monoclon
antibodi
mmab
specif
two
cchfv
envelop
glycoprotein
env
g
n
g
c
develop
neutral
assay
cell
mmab
g
c
g
n
prevent
cchfv
infect
howev
subset
g
c
mmab
protect
mice
passiveimmun
experi
nonneutr
g
n
mmab
effici
protect
anim
lethal
cchfv
challeng
thu
neutral
cchfv
like
depend
properti
antibodi
host
cell
factor
well
addit
nonneutr
antibodydepend
mechan
antibodydepend
cellmedi
cytotox
may
involv
vivo
protect
seen
mmab
mous
antibodi
could
induc
antimous
antigen
immun
respons
human
use
human
human
decreas
elimin
possibl
immunogen
effect
case
difficult
initi
experiment
program
aim
develop
fulli
human
mab
hmab
recogn
g
n
g
c
neutral
viru
use
phage
display
librari
g
n
g
c
mediat
viru
entri
suscept
cell
recent
express
character
membraneassoci
protein
current
avail
human
monoclon
antibodi
hmab
direct
epitop
g
n
g
c
plan
use
two
differ
procedur
env
express
noninfecti
materi
present
nativ
conform
mammalian
cell
surfac
associ
function
env
ii
recombin
express
solubl
env
product
env
close
nativ
conform
critic
import
mani
instanc
abil
elicit
potent
neutral
activ
oligomer
env
depend
retent
nativ
threedimension
structur
second
method
present
env
antigen
use
recombin
solubl
env
develop
abil
produc
solubl
form
glycoprotein
use
recombin
mammalian
express
system
often
allow
product
protein
form
unperturb
tertiari
quaternari
structur
exampl
viral
env
invari
oligomer
compos
homo
heterotrimer
tetramer
form
system
use
high
express
vector
tissu
cultur
often
allow
rapid
product
nativ
oligomer
version
type
protein
solubl
construct
easili
purifi
quit
use
analyz
structur
oligomer
natur
protein
thu
signific
amount
purifi
solubl
env
virus
avail
screen
pdl
pan
pdl
solubl
env
screen
highest
affin
binder
perform
use
standard
protocol
other
success
use
protocol
identif
hmab
direct
epitop
hiv
env
recent
develop
novel
methodolog
sequenti
antigen
pan
sap
base
altern
variou
env
pan
pdl
use
identifi
four
new
potent
broadli
hivneutr
human
monoclon
antibodi
fab
plan
use
sap
methodolog
env
conserv
neutral
epitop
virus
sap
approach
success
could
obtain
hmab
effect
sever
isol
addit
nhmab
specif
individu
isol
preliminari
experi
identifi
three
hmab
bind
specif
env
express
recombin
vaccinia
viru
character
neutral
activ
collabor
r
flick
epitop
map
zhu
et
al
prepar
